Menu
Search
|

Menu

Close
X

Cesca Therapeutics Inc KOOL.OQ (NASDAQ Stock Exchange Capital Market)

0.43 USD
+0.00 (+0.14%)
As of Jul 18
chart
Previous Close 0.43
Open 0.43
Volume 84,149
3m Avg Volume 102,704
Today’s High 0.45
Today’s Low 0.42
52 Week High 6.43
52 Week Low 0.37
Shares Outstanding (mil) 9.95
Market Capitalization (mil) 45.06
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
14
FY16
12
FY15
16
EPS (USD)
FY18
-0.543
FY17
-2.923
FY16
-7.208
FY15
-7.364
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
3.10
5.73
Price to Book (MRQ)
vs sector
1.46
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
11.35
16.84
LT Debt to Equity (MRQ)
vs sector
11.35
12.51
Return on Investment (TTM)
vs sector
-67.06
14.61
Return on Equity (TTM)
vs sector
-92.20
16.34

EXECUTIVE LEADERSHIP

Xiaochun Xu
Chairman of the Board, President, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Jeffery Cauble
Principal Financial Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Venkatesh Ponemone
Executive Director of India Operations, Director of Clinical and Scientific Affairs, Since
Salary: --
Bonus: --
Kimberly Ellner
Vice President of Manufacturing and Global Supply Chain, Since 2016
Salary: $164,000.00
Bonus: $6,000.00
Russell Medford
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2711 Citrus Rd
RANCHO CORDOVA   CA   95742-6228

Phone: +1916.8585100

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company's therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

SPONSORED STORIES